With Biogen Idec on the market [1], reporters are delving into the possibilities for the company and the potential fallout in the Boston biotech cluster that the company calls home. In one scenario, Cambridge, MA-based Biogen Idec and its big research operations are gobbled up whole by a Big Pharma company [2], with the region losing one of its oldest and biggest marquee names. But the biotech boosters in Beantown prefer to look on the sunny side of things, speculating about a deal that could enhance local work on biologics. Right now, biotech companies in general are fetching a premium [3] as pharma buys in to the next generation of therapies.

Biogen Idec's quarterly profit, meanwhile, slid 24 percent on a charge related to the consolidation of Cardiokine [4].

- read the report [5] from The Boston Globe
- here's a report [6] from the Wall Street Journal on Biogen Idec's numbers

Related Articles:
Biogen Idec in play after Icahn makes his move. Report [7]
Boston biotech booming as scientific research flourishes. Report [8]
The growing power of biotech. Report [9]
Biotech stocks surge as investors anticipate buyouts. Report [10]
Speculation soars over Pfizer's interest in biotech. Report [11]